Exploratory data presented for Active Biotech's ANYARA project

February 10, 2010 20:02 (CET)

Lund, Sweden, February 10, 2010 - Active Biotech AB (NASDAQ OMX Nordic:ACTI) has presented results from exploratory preclinical studies at the Keystone Symposia "Molecular and Cellular Biology of Immune Escape in Cancer" held in Keystone, Colorado, USA, February 7-12.

The complete poster "Combining tumor-targeted superantigens with anti-CTLA-4 results in synergistic anti-tumor effects in B16 tumor bearing mice" can be viewed at www.activebiotech.com. The results of the study demonstrate that TTS therapy can be further enhanced by specifically modulating the immune response in this experimental model.

The drug candidate ANYARA, using the TTS technology, is currently in pivotal Phase III clinical trials for Renal Cell Cancer. The primary endpoint is overall survival and results from these studies are expected first half of 2011.


Lund February 10, 2010
Active Biotech AB (publ)

 Tomas Leanderson

President and CEO  


For further information, please contact

Göran Forsberg

VP Investor Relations & Business Development

Tel: +46 (0)46 19 11 54



Notes to editors


ANYARA is a TTS (Tumor Targeting Superantigens) compound that makes the treatment of cancer tumor-specific. The development of ANYARA is mainly focused on renal cell cancer. Positive data was reported in connection with the interim analysis in Phase II/III and from clinical Phase I trials in lung cancer, renal cell cancer and pancreatic cancer. The median survival of 26.2 months observed for patients with advanced renal cancer and treated with ANYARA is twice the expected length. ANYARA has been granted orphan-drug status by the EMEA for the indication renal cancer. Information concerning the ongoing Phase III clinical trial is available at www.activebiotech.com and www.clinicaltrials.gov.


About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.


Active Biotech AB

PO Box 724, SE-220 07 Lund


Tel: +46 (0)46-19 20 00

Fax: +46 (0)46-19 11 00


Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on February 10, 2010.